These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 2036748)
1. Pharmacokinetics of newer drugs in patients with renal impairment (Part I). Fillastre JP; Singlas E Clin Pharmacokinet; 1991 Apr; 20(4):293-310. PubMed ID: 2036748 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of effect of impaired renal function on lamivudine pharmacokinetics. Bouazza N; Tréluyer JM; Ghosn J; Hirt D; Benaboud S; Foissac F; Viard JP; Urien S Br J Clin Pharmacol; 2014 Oct; 78(4):847-54. PubMed ID: 24750102 [TBL] [Abstract][Full Text] [Related]
3. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976 [TBL] [Abstract][Full Text] [Related]
4. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Sobue S; Tan K; Layton G; Leclerc V; Weil A Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of sparfloxacin in patients with renal impairment. Dorr MB; Johnson RD; Jensen B; Magner D; Marbury T; Talbot GH Clin Ther; 1999 Jul; 21(7):1202-15. PubMed ID: 10463518 [TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794 [TBL] [Abstract][Full Text] [Related]
7. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005). O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Gupta SK; Kantesaria B; Glue P Drug Discov Ther; 2013 Aug; 7(4):158-63. PubMed ID: 24071578 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment. Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis. Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function. Devriese LA; Witteveen PE; Mergui-Roelvink M; Smith DA; Lewis LD; Mendelson DS; Bang YJ; Chung HC; Dar MM; Huitema AD; Beijnen JH; Voest EE; Schellens JH Br J Clin Pharmacol; 2015 Aug; 80(2):253-66. PubMed ID: 25677219 [TBL] [Abstract][Full Text] [Related]
14. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. Kremer JM; Hamilton RA J Rheumatol; 1995 Nov; 22(11):2072-7. PubMed ID: 8596147 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of recombinant soluble thrombomodulin in disseminated intravascular coagulation patients with renal impairment. Hayakawa M; Yamamoto H; Honma T; Mukai N; Higashiyama A; Sugano M; Kubota N; Uegaki S; Sawamura A; Gando S Shock; 2012 Jun; 37(6):569-73. PubMed ID: 22552020 [TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of angiotensin converting enzyme inhibitors in patients with renal impairment. Begg EJ; Bailey RR; Lynn KL; Robson RA; Frank GJ; Olson SC J Hypertens Suppl; 1989 Sep; 7(5):S29-32. PubMed ID: 2681603 [TBL] [Abstract][Full Text] [Related]
17. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease. Zhang L; Xu N; Xiao S; Arya V; Zhao P; Lesko LJ; Huang SM J Clin Pharmacol; 2012 Jan; 52(1 Suppl):79S-90S. PubMed ID: 22232757 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function. Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Periclou A; Ventura D; Rao N; Abramowitz W Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of ceftriaxone in subjects with renal insufficiency. Kowalsky SF; Echols RM; Parker MA Clin Pharm; 1985; 4(2):177-81. PubMed ID: 3987216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]